

SCOLR Pharma, Inc.  
Form 4  
November 08, 2005

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
TAGLICH MICHAEL N

(Last) (First) (Middle)

3625 132ND AVENUE SE SUITE 300

(Street)

BELLEVUE, WA 98006

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
SCOLR Pharma, Inc. [DDD]

3. Date of Earliest Transaction  
(Month/Day/Year)  
11/04/2005

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Beneficial Ownership (Instr. 4)
				(A) or (D)	Amount		
				Code	V		
					Amount		
				(D)	Price		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474 (9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	4. Transaction Code	5. Number of Derivative Securities	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)

Edgar Filing: SCOLR Pharma, Inc. - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year)	(Instr. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number of Shares
Stock Option (right to buy)	\$ 4.61	11/04/2005	A	100,000					(1)(2)(3)	11/03/2015	Common Stock	100,000
Stock Option (right to buy)	\$ 4.62	11/04/2005	A	9,375					11/04/2005	11/03/2015	Common Stock	9,375

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TAGLICH MICHAEL N 3625 132ND AVENUE SE SUITE 300 BELLEVUE, WA 98006		X		

## Signatures

Michael N. Taglich  
11/08/2005  
 \*\*Signature of Reporting Person                      Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) (1) Option to vest over 2 years in 24 equal installments commencing December 4, 2005.
- If at the end of one (1) year of continuous service, the shares of common stock have traded at a price per share in excess of 125% of the exercise price on a volume weighted average price ("VWAP") basis for a continuous period of thirty (30) trading days during the first
- (2) year of service, then 50,000 shares issuable upon exercise of the option will become vested and exercisable. If at the end of year one (1) of continuous service, the common stock has not traded at a price per share in excess of 125% of the exercise price on a VWAP basis for a continuous period of thirty (30) trading days, then none of the options will become vested and exercisable. (continued)
- Notwithstanding foregoing, if during the twelve (12) months beginning November 4, 2006 and ending on December 4, 2007 the shares of common stock have traded on a stock exchange at a price per share in excess of 150% of the exercise price based on a VWAP basis for a continuous period of thirty (30) trading days, then all of the shares of common stock issuable upon exercise of the option will become
- (3) vested. If during the twelve (12) months beginning on December 4, 2006 and ending on the, December 4, 2007 shares of common stock have not traded at a price per share in excess of 150% of the exercise price on a VWAP basis for a continuous period of thirty (30) trading days at any time after the grant date, then no more than 50,000 the shares of common stock issuable upon exercise of the Option will have become vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.